Biocompatibility Innovation

BCI congratulates Giulio Sturaro, Quality Assurance Manager and laboratory scientist, for having obtained the following AICQ SICEV certifications. 📌 Auditor of Medical Device Single Audit Program 📌Auditor / Lead Auditor of Management Systems: Audit Methodology 📌Auditor / Lead Auditor ISO 9001:2015 Quality Management Systems 📌Quality Assurance & Regulatory Affairs for Medical Devices and in Vitro Diagnostics (MD-IVD) Giulio's new qualifications ensure that BCI's laboratory remains state of the art and is compliant with best practices and industry standards. #BiocompatibilityInnovation #LifeSciences #MedTech #Biocompatibility

Let us take some time to discuss the latest in valve leaflet treatment. All bioprosthetic valves fail eventually - it's an inexorable and irreversible immunologic process that occurs over time, 2, 5, 10, 12 years or more after implantation. But it happens. Our current understanding is limited but the immunologic changes are characteristic for tissue rejection. Often patients ask us, "Will my valve reject since its an animal?" The correct answer isn't "No." - the correct answer is "Yes, over time your valve will reject and eventually fail."    The antigen galactose alpha 1,3 galactose (alpha-Gal epitope), which is found in non-primate animals, plays a major role in BHV degeneration and has been recently shown to be endemic in up to 30-40% of the US population. This growing phenomenon highlights the effects that meat consumption (pork, beef) has on our bodies and immunologic system. What's the consequence? Increased activity to animal-based products that are implanted in our body, such as heart valves. As shown in a recent analysis (TCT 2023), alpha-gal immunoreactivity is very high, across all types of pericardial and porcine surgical valves and TAVR valves (see figure below).  There is a critical need to block alpha-gal in medical implants, and Biocompatibility Innovation has been leading with way. We have been working to utiliize a novel leaflet coating treatment that blocks over 99% of alpha-gal sites on leaflets (see figure below), which may have important clinical effects in extending the life of bioprosthetic valve leaflets. The future is bright - onward we go! Stay tuned for more updates...

With PCR #LondonValves2024 behind us, #BCI would like to #thank professors Isaac George M.D., FACC, FACS and Bruno Melica for representing our company at the prestigious conference. Their meaningful and continued contributions to interventional #cardiology are helping to reshape the future of #implantable medical devices.   Speaking as BCI #Clinical Advisory #Board members, their broad experience, research and insight have once again played a significant role in bringing #BCI's #technology to a broader audience. #BiocompatibilityInnovation #PCRLV #LifeSciences #MedTech #Biocompatibility

Learn about nascent BCI technology at PCR #LondonValve November 24-26. A cross-disciplinary three-day program focused on transcatheter therapies for valvular heart disease, representing a unique opportunity to share and advance patient care in each fast-moving field of the Heart Team. Two outstanding members of #BCI's Clinical Advisory Board will present their latest research. Professor Isaac George M.D., FACC, FACS will present a #poster on a new technology for the third generation of #polymer heart valves. We hope you join us for Professor Bruno Melica's presentation on BCI's treatment aimed at overcoming the constraints of #glutaraldehyde during the afternoon session of the #program on Sunday, November 24th. BCI would like to recognize and thank Professors #IsaacGeorge and #BrunoMelica for their contributions and for advancing new solutions for prosthetic heart valves. #BiocompatibilityInnovation #PCRLV #LifeSciences #MedTech #Biocompatibility

BCI announces its #Ecosystem Membership with Bio4Dreams, an incubator of innovative startups in #LifeSciences. By joining #Bio4Dreams, #BCI will have access to dedicated services and a wide ranging, qualified #network of partners that work to support the most innovative Italian #startups in the field of #biomedical research. We are honored to join such a comprehensive #network alongside other major players in #Medtech. #Bio4DreamsNetwork #LifeSciences #MedTech #Biocompatibility

Great opportunity for BCI in San Francisco to be embedded in the Silicon Valley network and also to know great Italian enterpreneurs and great Italian companies with very valuable and high science projects!

#BioCompatibilityInnovation thanks INNOVIT - Italian Innovation and Culture Hub for paving its way to #SiliconValley. Last week our CEO, Alessandro Gandaglia was in San Francisco for the #Call4innovit program, an immersive experience and a valuable #opportunity to #network with leading experts as well as to strengthen Silicon Valley's innovation #stakeholder relationships. #biocompatibility #BCIproject #BCItechnology #LifeScience #digitalHealth

We are pleased to announce that #BiocompatibilityInnovation will participate in #NYVALVES2024, The Structural Heart Summit (NYC - June 5th to 7th, 2024). On Friday morning, #June7th, Dr. Isaac George M.D., FACC, FACS will give a #lecture on our cutting-edge #coating technology for the third generation of polymer heart valves, presenting and supporting #BCItechnology. Join us at the #Summit: https://lnkd.in/eYJYMnig #biocompatibility #heartvalve #BCIproject

We are very pleased to announce that Shuki Porath has joined the BCI family as a member of our Board of Directors, and our #StrategicBoard. With over 26 years of experience in the #MedTech industry, Shuki has a proven track record in top #management positions.   We asked Mr. #Porath what excites him about the #BCIproject and what he expects in this undertaking. He responded: “I have dedicated most of my career to the #medical #device industry, seeking opportunities to make a difference in peoples’ lives. The #technology developed and the work being done by BCI has the potential to significantly enhance the quality of life for a vast number of patients, by augmenting the #biocompatible performance of every #implantable medical device. It is inspiring to be a part of something so meaningful that can #positively impact our world."   We are eager to have him on #board and believe he will make a valuable contribution to our company as we embark on this #BCIjourney together. Find out more: https://lnkd.in/dPaf_UVk #BioCompatibilityInnovation #BCIteam #BCItechnology #tissuetreatment #medicaldevice #qualityoflife

#BioCompatibilityInnovation is excited to announce that we've been selected as one of the most promising Italian innovative entrepreneurial ventures to take part in #Call4INNOVIT, the tailored #acceleration program offered by INNOVIT - Italian Innovation and Culture Hub. #INNOVIT is the first Italian Innovation and Culture Hub in San Francisco, promoted by the Ministero degli Affari Esteri e della Cooperazione Internazionale, in collaboration with the #Embassy of #Italy in #Washington and the General #Consulate in #SanFrancisco, and managed with the support of the ITA - Italian Trade Agency and the Istituto Italiano di Cultura San Francisco. Thanks to INNOVIT - Italian Innovation and Culture Hub for this exciting opportunity to propel our #growth and engage with Silicon Valley's innovation stakeholders. #biocompatibility #BCIproject #BCItechnology #LifeScience #digitalHealth